A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Toludesvenlafaxine (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Luye Pharma Group
Most Recent Events
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 24 Jul 2023 Status changed from planning to not yet recruiting.
- 25 Mar 2022 New trial record